Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Mark Buyyounouski MD MS
Closed to Accrual
The primary objective is to demonstrate that hypofractionated post-prostatectomy radiotherapy (HYPORT) does not increase patient-reported GI and GU symptoms over conventionally fractionated post-prostatectomy (COPORT) at the 2-year time point.
Patients with adenocarcinoma of the prostate treated primarily with radical prostatectomy; pathologic T-classification pT2 or pT3; pathologic N-classification pN0 or pNX; and no clinical evidence of regional lymph node metastasis.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.